FDA Peptide Tracker

Cagrilintide: live FDA regulatory status

Long-acting amylin analog · Investigational

The two signals

Plain-English verdict: amber.

Regulatory status: Investigational (Phase 3).

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Join waitlist

What happens next

CagriSema / REDEFINE readouts — 2026–2027

Regulatory timeline

Cagrilintide: common questions

Is Cagrilintide available in 2026?
No. Cagrilintide is investigational — it is in clinical trials and has not been approved by the FDA for any use. There is no legal route to a prescription outside a trial.
Can I get Cagrilintide right now?
No. Cagrilintide is a status list only — join it and we will write to you if and when an approved product exists. Anything sold as Cagrilintide today is not a regulated medicine.
Is Cagrilintide the same as a compounded peptide?
No, and conflating them is a common error. Cagrilintide is an investigational drug in a manufacturer's trial programme. Compounded peptides are prepared by a pharmacy for an individual patient under 503A. Different pathways, different rules.
What happens next for Cagrilintide?
CagriSema / REDEFINE readouts, 2026–2027. Trial readouts are not approvals, and approval would be the manufacturer's, not ours.

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board or this molecule's knowledge-base monograph.

Embed this card on your site · free, CC BY 4.0, no key.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.